These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8070483)

  • 21. Effect of recombinant hirudin (LU 52369) on reocclusion rates after thrombolysis in rabbits.
    Rübsamen K; Eschenfelder V
    Haemostasis; 1991; 21 Suppl 1():93-8. PubMed ID: 1894200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
    Kornowski R; Eldor A; Werber MM; Ezov N; Zwang E; Nimrod A; Chernine A; Finkelstein A; Panet A; Laniado S; Keren G
    Coron Artery Dis; 1996 Dec; 7(12):903-9. PubMed ID: 9116933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
    Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.
    Stassen JM; Rapold HJ; Vanlinthout I; Collen D
    Thromb Haemost; 1993 May; 69(5):454-9. PubMed ID: 8391726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of adjunctive intrathrombic heparin with pulse spray thrombolysis in rabbit inferior vena cava thrombosis.
    Valji K; Bookstein JJ
    Invest Radiol; 1992 Nov; 27(11):912-7. PubMed ID: 1464509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
    Rapold HJ; Lu HR; Wu ZM; Nijs H; Collen D
    Blood; 1991 Mar; 77(5):1020-4. PubMed ID: 1899806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated protein C and antithrombin-III activity during arterial thrombolysis with recombinant tissue-type plasminogen activator in rabbits.
    Kornowski R; Battler A
    Coron Artery Dis; 1993 Dec; 4(12):1115-8. PubMed ID: 8162244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
    Jang IK; Gold HK; Ziskind AA; Fallon JT; Holt RE; Leinbach RC; May JW; Collen D
    Circulation; 1989 Apr; 79(4):920-8. PubMed ID: 2494006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis.
    Leidy EM; Stern AM; Friedman PA; Bush LR
    Thromb Res; 1990 Jul; 59(1):15-26. PubMed ID: 1975957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
    Valji K; Arun K; Bookstein JJ
    J Vasc Interv Radiol; 1995; 6(1):91-5. PubMed ID: 7703589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcatheter thrombolysis with high-dose bolus tissue plasminogen activator in iatrogenic arterial occlusion after femoral arterial catheterization.
    Tsetis DK; Kochiadakis GE; Hatzidakis AA; Skalidis EI; Chryssou EG; Tritou IN; Vardas PE; Gourtsoyiannis NC
    Cardiovasc Intervent Radiol; 2002; 25(1):36-41. PubMed ID: 11907772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective thrombolysis in acute deep vein thrombosis: evaluation of adjuvant therapy in vivo.
    Roy S; Brosstad F; Sakariassen KS
    Cardiovasc Intervent Radiol; 1999; 22(5):403-10. PubMed ID: 10501893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
    Chen L; Nichols WW; Mattsson C; Teger-Nilsson AC; Saldeen TG; Mehta JL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1276-83. PubMed ID: 8667188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model.
    Bagge L; Wahlberg T; Holmer E; Tydén H; Nyström SO; Malm T
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):265-72. PubMed ID: 8054460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.